Toronto, Ontario (Newsfile Corp. - September 28, 2023) - PurMinds NeuroPharma ("PurMinds" or the "Company"), a neuroscience company with a robust clinical pipeline combining small molecules, psychedelic compounds and other modalities, pursuing breakthrough therapeutic solutions for neurological disorders hallmarked by neurodegeneration, today announced completion of acquisition of a small molecule novel chemical entity (NCE) known as SW-200, a non-hydroxamic acid that shows superior histone dea
PurMinds NeuroPharma: PurMinds Appoints Leading Drug Designer, Dr Alan Kozikowski to the Scientific Advisory Board finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
NEW YORK, Jan. 18, 2022 via InvestorWire Microdose Psychedelic Insights, the leading guide to the business of psychedelics will be hosting the upcoming Psychedelic Capital: January 2022.